All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-11-25T12:45:19.000Z

When and how should treatment be modified for older patients with HL?

By Ellen Jenner, Kreena Mistry, Jack Ladhams
Featured
Astrid Pavlovsky
Nov 25, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in Hodgkin lymphoma.

Bookmark this article

During the International Symposium on Hodgkin Lymphoma (ISHL) 2022 meeting, the Lymphoma Hub spoke with Astrid Pavlovsky, Fundaleu, Buenos Aires, AR. We asked, When and how should treatment be modified for older patients with HL?

When and how should treatment be modified for older patients with HL?

Pavlovsky begins by outlining why patients with HL >60 years of age typically have poor outcomes compared with younger patients. Pavlovsky then discusses the challenges faced when treating older patients with HL and reviews the latest clinical trial data for novel agents and combination therapies in this difficult-to-treat population.

More about...
Brentuximab vedotinHodgkin lymphomaNivolumabThe 12th International Symposium on Hodgkin Lymphoma (ISHL12)Treatment of older patients with lymphoma and CLL

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Real-world outcomes of very elderly lymphoma patients in Sweden

The results of this real-world analysis in Swedish very elderly lymphoma patients, indicate that in DLBCL and MZL current active treatments offer a significantly superior survival...

Nov 29, 2018
Add bookmark

Real-world outcomes of very elderly lymphoma patients in Sweden

The results of this real-world analysis in Swedish very elderly lymphoma patients, indicate that in DLBCL and MZL current active...

Nov 29, 2018
Add bookmark

Should age affect eligibility for autologous stem cell transplant in elderly lymphoma patients?

This study demonstrated that elderly patients are still viable candidates for ASCT, with good clinical outcomes and acceptable expected toxicities.

Jan 25, 2018
Add bookmark

Should age affect eligibility for autologous stem cell transplant in elderly lymphoma patients?

This study demonstrated that elderly patients are still viable candidates for ASCT, with good clinical...

Jan 25, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox